Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Clostridium difficile

Clostridium difficile

Nov 08, 2018

Meridian Bioscience Q4 Revenues Grow 7 Percent

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

Oct 23, 2018

GenePOC's Investment in Small Molecular Diagnostic Panels Validated by Medicare Decision, Company Says

Premium

Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.

Oct 23, 2018

GenePOC C. Diff MDx Approved in Canada

The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.

Jul 31, 2018

Meridian Bioscience Q3 Revenues Grow 3 Percent

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

Jun 19, 2018

First Light Bio Developing Single-Molecule Counting Tech to Detect C. Diff. Toxins

Premium

The platform counts single target molecules in stool samples within 30 minutes and without sample preparation to detect C. diff. toxins.

Apr 24, 2018

Meridian Eyes Physician Office Space With Curian Immunoassay Reader

Premium

The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.

Apr 11, 2018

First Light Biosciences Developing Rapid Syndromic ID/AST System Using Digital Imaging

Premium

The system will perform 200 multiplexed pathogen ID tests or 40 AST tests in one eight-hour shift on a random access, fully automated benchtop instrument.

Jan 12, 2018

JPM Healthcare Day 4: Luminex, Natera, and Oxford Immunotec

Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.

Dec 12, 2017

Heroin Detection Assay, Kidney Injury System Cleared by FDA in November

Microgenics, Astute Medical, and Siemens were among the firms whose tests and/or systems were cleared by the FDA for marketing last month.

Nov 28, 2017

GenePOC C. Diff Test Receives FDA Approval

The Québec-based firm launched the test, which detects the toxin B gene of toxigenic C. diff strains directly from stool samples, in the US today.

Pages

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.